Unixell
1 known investors
Unixell Biotech develops advanced cell therapy platforms including reprogramming, stem cell differentiation, lineage tracing, and gene editing technologies to create neural cell therapeutics for clinical applications. The company's lead program is UX-DA001, a midbrain dopamine precursor cell therapy for Parkinson's disease, which has received clinical trial approval from Chinese and US regulatory authorities.
Investors · 1
In the news
Frequently asked questions
- What does Unixell do?
- Unixell Biotech develops advanced cell therapy platforms including reprogramming, stem cell differentiation, lineage tracing, and gene editing technologies to create neural cell therapeutics for clinical applications. The company's lead program is UX-DA001, a midbrain dopamine precursor cell therapy for Parkinson's disease, which has received clinical trial approval from Chinese and US regulatory authorities.
- Who are Unixell's investors?
- Unixell's investors include Pan-Lin Capital.